The Seventh International Renal Meeting with *Mayo Clinic* in Sardinia

Sa Manifattura, Cagliari (Italy), May 29th - June 1st, 2025

Congress Presidents

Antonello Pani, Fernando Fervenza, Sanjeev Sethi, Dario Roccatello

TOPICS

NEWS AND NEW ERA OF GN TREATMENT One Day, 50 min each talk 25 min Lesson plus 25 min discussion with two young chairs plus a "strong" panel of discussants plus audience discussion MN, MCD and FSGS, Amyloidosis, LN, AAV, DKD, Alport Syndrome
FABRY DISEASE PERSONALIZED THERAPY WITH "OLD" AND NEW DRUGS Enzyme Replacement Therapy (Ert): Agalsidase Alfa, Agalsidase Beta; Chaperone Therapy (Migalastat); Pegunigalsidase Alfa; Investigational Therapies
HEMODIALYSIS and ABSORPTION TECHNIQUES Hemoadsorption-hemodialysis (HAHD) in ESKD patients, Uremic Toxins and Cardiovascular Damage, The Choice of Hemodialysis membrane
TREATMENT OF CKD IN IMMUNE-MEDIATED GNs: CHANGING THE PARADIGM (SGLT2i, MRA, endothelin A receptor antagonists, GLP-1 receptor agonist, others)
COMPLEMENT MEDIATED DISEASE: use of anti-complement drugs (Update) (Role of "old" drugs and development of new drugs targeting complement)
ONCO-NEPHROLOGY: ANTICANCER DRUGS TOXICITY and MYELOMA KIDNEY Assessment of GFR in Patients with Cancer, Acute Kidney Disease in patients treated with targeted agents and ICI, CKD, and RRT in cancer patients, Classification and Management of MGRS
KIDNEY AND PREGNANCY Thrombotic microangiopathies and pregnancy, Pre-Eclampsia (bench and bed-side research), gender-related hypertension, Pre-Eclampsia in CKD patients,
GENETICS FOR NEPHROLOGISTS (CKD and others) Genetic Testing in Kidney Diseases
KIDNEY TRANSPLANTATION The influence of minor-HLA loci on graft survival, Treatment of Chronic Ab mediated Rejection, Anti-cancer therapy in transplant patients
TREATMENT OF PRINCIPAL ELECTROLYTE AND ACID-BASE DISORDERS Standard and New Treatments for Hyperkalemia
NEW STATEMENTS ON ANEMIA TREATMENT IN ADVANCED CKD How to improve management of iron therapy? Use of ESAs and use of HIF prolyl-hydroxylase inhibitor
APPLICATION OF ARTIFICIAL INTELLIGENCE IN NEPHROLOGY Generative AI in Critical Care Nephrology

The Seventh International Renal Meeting with Mayo Clinic in Sardinia will be held in Cagliari from May 29th to June 1st 2025.

After fourteen years the International Meeting with Mayo Clinic is now in its seventh edition.

Thanks to the experience acquired in the past six editions and the appreciation expressed by participants other than the lecturers' high quality for the debate, we are encouraged to extend the time dedicated to the discussion for each topic. During the upcoming edition of the meeting, furthermore, the structural organization of each subject recently debated at major international conferences will be prevalent, featuring 25-minutes lectures followed by 25-minutes discussions with two young chairs and an expert "strong" panel of discussants plus audience discussion.

Ten sessions, five lectures and two lunch meetings have been planned.

As far as clinical nephrology is concerned, considering the new therapeutics approach that has recently entered everyday use in clinical practice, we will focus our attention on the "New ERA of GN treatment" (Primary and Secondary GNs). The first day of the meeting is dedicated to presenting and discussing the new scheme of therapeutic approach to Membranous Nephropathy, MCD and FSGS, IgA Nephropathy, Lupus Nephritis, ANCA Related Vasculitis, MCGN, and DKD. The focus will be on all new immunosuppressive drugs used in the therapy of induction and maintenance of the above-listed Glomerulonephritis, such as new biologic drugs, anti-BAFF therapy, anti-complement therapies and also new anticalcineurin drugs and others. Concerning glomerulonephritis (and DKD), the focus will also be on the anti-progression of renal damage drugs such as SGLT2 inhibitors, anti-endothelin, and non-steroidal selective MRA. All new therapies, such as Semaglutide and GLP-1 receptor agonists, ACE inhibitors, sartans and other new prospective therapies still under research will be addressed.

One lunch meeting will be focused on "old" and new drugs for personalized therapy of Fabry Disease [enzyme replacement therapy (ERT): agalsidase alfa, agalsidase beta; chaperone therapy (migalastat); pegunigalsidase alfa; investigational therapies].

One session will update participants on kidneys and pregnancy and the treatment of hypertension during pregnancy.

Two sessions are dedicated to Onco-Nephrology and the best use of onco-drugs to avoid as many renal adverse effects as possible.

The session on renal transplantation will mainly focus on the therapy of acute rejection and antibody-mediated chronic rejection (ABMR), the influence that minor HLA antigens have on these types of rejection, and how they condition the immunosuppressive therapy scheme.

A dedicated session will address key insights about how genetics determines and influences many kidney diseases, including chronic kidney disease and major monogenic kidney diseases (Alport syndrome).

Finally, lectures on new approaches to treating hyperkalemia, anemia in uremia and teledialysis in PD patients will be held.

A lunch meeting will be dedicated to how artificial intelligence (AI) can help nephrologists predict the progression of kidney damage. Finally, during the opening ceremony, two readings specific to Sardinia will be delivered to our Italian and foreign guests: one on the genetics of the origin of the Sardinian people and the other one on the history of Sardinian Nuragic culture and how artificial intelligence can help the exploration of Nuraghi and foster UNESCO recognition of that culture.

We have chosen the same time of the year as the last edition, trusting in the good weather of early summer in Cagliari. On behalf of Fernando Fervenza, Sanjeev Sethi and Dario Roccatello, along with Honorary Presidents Richard Glassock and Claudio Ponticelli I am pleased to invite you all to attend this event.

We look forward to seeing you in Cagliari and we believe that the quality of the scientific programme, together with Sardinian hospitality, will guarantee a successful outcome as in the previous editions.

Antonello Pani

SCIENTIFIC PROGRAMME

THURSDAY MAY 29TH

LESSONS FOR YOUNG NEPHROLOGISTS		
Chairs	**Giocambattista Capasso (Naples, Italy), Giusto Viglino (Alba, Italy), Vincenzo La Milia (Lecco, Italy)**	
1:20 p.m. - 1:40 p.m.	Multitarget treatment in CKD	**Maura Ravera (Genoa, Italy)**
1:40 p.m. - 2:00 p.m.	Symptomatic management of nephrotic syndrome	**Pasquale Esposito (Genoa, Italy)**
2:00 p.m. - 2:20 p.m.	The oncogenic role of uremic toxins	**Adelina Simeoni (Naples, Italy)**
2:20 p.m. - 2:40 p.m.	Prescription of HD treatment in chronic patients	**Antonio Santoro (Bologna, Italy)**
2:40 p.m. - 3:00 p.m.	Enhancing Peritoneal Dialysis Management through Teledialysis and Remote Monitoring Technologies	**Paolo Lentini (Bassano del Grappa, Italy)**
3:20 p.m. - 3:40 p.m.	Diagnosis and treatment of hyponatremia	**Francesco Trepiccione (Naples, Italy)**
3:40 p.m. - 4:00 p.m.	Hyperuricemia in CKD, Hypertension, and Cardiovascular Disorders: Role and Treatment Approaches	**Francesca Viazzi (Genoa, Italy)**
4:00 p.m. - 4:30 p.m.	Discussion	

PEDIATRIC SESSION		
Chairs	**Licia Peruzzi (Turin, Italy), Giuseppe Masnata (Cagliari, Italy)**	
SESSION I: GENETICS, METABOLISM, AND BIOMARKERS IN PEDIATRIC KIDNEY DISEASES		
Table of discussants	**Cristiana Angioni (Cagliari, Italy), Francesco Emma (Rome, Italy), Diana Zepeda-Orozco (Columbus, USA)**	
12:40 p.m. - 1:00 p.m.	Inherited errors of metabolism and renal diseases	**Marta Balzarini (Cagliari, Italy)**
1:00 p.m. - 1:20 p.m.	Multidisciplinary approaches for elucidating genetics and molecular pathogenesis of urinary tract malformations	**Simone Sanna Cherchi (New York, USA)**
1:20 p.m. - 1:40 p.m.	Typical and Atypical Hemolytic Uremic Syndrome in Infants and Children	**Mario Giordano (Bari, Italy)**
1:40 p.m. - 2:00 p.m.	Primary Hyperoxaluria: Recent Advances	**Licia Peruzzi (Turin, Italy)**
2:00 p.m. - 2:20 p.m.	Urinary biomarkers associated with acute kidney injury in children: from bench to bedside	**Diana Zepeda-Orozco (Columbus, USA)**
2:20 p.m. - 2:50 p.m.	Plenary Discussion	
SESSION II - THERAPEUTIC APPROACHES AND CLINICAL MANAGEMENT IN PEDIATRIC KIDNEY DISEASES		
Table of discussants	**Franca Zurrida (Cagliari, Italy), Gianmarco Ghiggeri (Genoa, Italy)**	
2:50 p.m. - 3:10 p.m.	Recurrent Urinary Tract Infections: The Role of Bladder and Bowel Dysfunction	**Giuseppe Masnata (Cagliari, Italy), Valeria Manca (Cagliari, Italy)**
3:10 p.m. - 3:30 p.m.	New insights into treatment of pediatric NS	**Gianmarco Ghiggeri (Genoa, Italy)**
3:30 p.m. - 3:50 p.m.	Mycophenolate model through levels monitoring in children with relapse of nephrotic syndrome	**Giovanni Montini (Milan, Italy)**
3:50 p.m. - 4:10 p.m.	Hypophosphatemic Rickets: Recent Advances	**Francesco Emma (Rome, Italy)**

4:10 p.m. - 4:40	Plenary Discussion

OPENING CEREMONY		
Chairs	**Antonello Pani (Cagliari, Italy), Fernando Fervenza (Rochester, MN, USA), Dario Roccatello (Turin, Italy)**	
5:30 p.m. - 6:00 p.m.	Greetings from the Authorities	
6:00 p.m. - 7:00 p.m.	Opening Lectures: The Future of Nephrology Negotiating the Dynamic Landscape of Therapies for IgA Nephropathy	 **Luca De Nicola (Naples, Italy) - *Virtual*** **Richard Glassock (Los Angeles, CA, USA)**
7:00 p.m. - 7:30 p.m.	Genetic History of Sardinians	**Francesco Cucca (Sassari, Italy)**
7:30 p.m. - 8:00 p.m.	Exploring Nuraghi with Artificial Intelligence	**Pierpaolo Vargiu (Cagliari, Italy)**
8:00 p.m.	Welcome Cocktail	

FRIDAY MAY 30TH

NEWS AND NEW ERA OF GN TREATMENT (first part)		
Chairs	**Nicola Lepori (Cagliari, Italy)**	
Table of Discussants	**Sanjeev Sethi (Rochester, MN, USA), Glen Markowitz (New York, NY, USA), Federico Alberici (Brescia, Italy), Giuseppe Gigliotti (Eboli, Italy), Antonello Pani (Cagliari, Italy), Paola Bianco (Cagliari, Italy)**	
8:00 a.m. - 9:20 a.m.	The new approach to the treatment of AAV	**Dario Roccatello (Turin, Italy)**
	PLEX in AAVGN: Time to let go of the old	**Ulrich Specks (Rochester, MN, USA)**
9:20 a.m. - 10:40 a.m.	Treatment of Lupus Nephritis: Standard of care	**Isabelle Ayoub (Columbus, OH, USA)**
	Lupus Nephritis: Redefining treatment goals	**Fernando Fervenza (Rochester, MN, USA)**
10:40 a.m. - 11:30 a.m.	Novel pathogenetic mechanisms of kidney injury and novel treatment for Alport Syndrome	**Alessia Fornoni (Miami, FL, USA)**
11:30 a.m. - 12:20 p.m.	The new approach to the treatment of DKD	**Loreto Gesualdo (Bari, Italy)**
12:20 p.m. - 1:20 p.m.	**LUNCH LECTURE: PATHOLOGY OF ONCO-NEPHROLOGY** Discussant: **Antonella Barreca (Turin, Italy)**	**Glen Markowitz (New York, NY, USA)**

NEWS AND NEW ERA OF GN TREATMENT (second part)		
Chairs	**Savino Sciascia (Turin, Italy), Andrea Angioi (Cagliari, Italy)**	
Table of Discussants	**Fernando Fervenza (Rochester, MN, USA), Dario Roccatello (Turin, Italy), Domenico Santoro (Messina, Italy), Antonella Barreca (Turin, Italy), Paola Bianco (Cagliari, Italy)**	
1:20 p.m. - 2:10 p.m.	Precision medicine in MCD and primary FSGS: is anti-nephrin the new anti-PLA2R?	**Pierre Ronco (Paris, France)**
2:10 p.m. - 3:00 p.m.	Preventing Relapses in Childhood Nephrotic Syndrome	**Francesco Emma (Rome, Italy)**
3:00 p.m. - 3:50 p.m.	How to treat patients with antiphospholipid syndrome in 2025?	**Savino Sciascia (Turin, Italy)**
3:50 p.m. - 4:40 p.m.	How Mass Spec has changed the diagnostic of MN and Amyloidosis	**Sanjeev Sethi (Rochester, MN, USA)**
4:40 p.m. - 5:30 p.m.	The new approach to the treatment of Amyloidosis	**Giovanni Palladini (Pavia, Italy)**

5:30 p.m. - 6:00 p.m.	The new era of CKD treatment in immune-mediated GNs: The role of SGLT2i, MRAs, endothelin A receptor antagonists, GLP-1 receptor agonist and beyond	**Antonello Pani (Cagliari, Italy)**

SATURDAY MAY 31ST

ONCO-NEPHROLOGY AND ANTICANCER DRUG TOXICITY		
Chairs	**Maurizio Gallieni (Milan, Italy), Matteo Floris (Cagliari, Italy)**	
Table of Discussants	**Mark Perazella (New Haven, CT, USA), Giovambattista Capasso (Naples, Italy), Laura Cosmai (Milan, Italy), Adelina Simeoni (Naples, Italy), Valeria Pusceddu (Cagliari, Italy)**	
8:00 a.m. - 8:20 a.m.	ADQI initiative: Onco-Nephrology in anti-cancer therapy	**Mitchell Rosner (Charlottesville, VA, USA)**
8:20 a.m. - 8:40 a.m.	Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology	**Sandra Herrmann (Rochester, MN, USA)**
8:40 a.m. - 9:00 a.m.	Acute Kidney Disease in patients treated with immune checkpoint inhibitors	**Roberta Fenoglio (Turin, Italy)**
9:00 a.m. - 9:30 a.m.	Plenary Discussion	

ONCO-NEPHROLOGY: MANAGEMENT OF LONG-TERM COMPLICATIONS		
Chairs	**Diana Zepeda-Orozco (Columbus, Ohio, USA)**	
Table of Discussants	**Mitchell Rosner (Charlottesville, VA, USA), Mark Perazella (New Haven, CT, USA); Giovanbattista Capasso (Naples, Italy), Laura Cosmai (Milan, Italy), Adelina Simeoni (Naples, Italy)**	
9:30 a.m. - 09:50 a.m.	The management of renal function in patients undergoing nephrectomy	**Francesco Trevisani (Milan, Italy)**
09:50 a.m. - 10:20 a.m.	Chronic Kidney Disease in Cancer Survivors.	**Rimda Wanchoo (New York, NY, USA)**
10:10 a.m. - 10:30 a.m.	Renal Replacement Treatment in patients undergoing anticancer therapy	**Matteo Floris (Cagliari, Italy)**
10:30 a.m. - 10:50 a.m.	The role of risk score in predicting severe acute kidney injury after intravenous cisplatin	**Ilya Glezerman (New York, NY, USA)**
10:50 a.m. - 11:20 a.m.	Plenary Discussion	

Chair	**Antonello Pani (Cagliari, Italy)**	
11:20 a.m. - 12:00 p.m.	Complement dysregulation and how to use anti-complement drugs in renal diseases: a new era.	**Erica Daina (Bergamo, Italy)**

SATURDAY MAY 31ST

LUNCH MEETING: FABRY DISEASE PERSONALIZED THERAPY WITH "OLD" AND NEW DRUGS		
Chair	**Antonello Pani (Cagliari, Italy)**	
12:00 p.m. – 12:15 p.m.	Enzyme replacement therapy (ert): Agalsidase alfa	**Sandro Feriozzi (Roma, Italy)**
12:15 p.m. - 12:30 p.m.	Enzyme replacement therapy (ert): Agalsidase beta	**Renzo Mignani (Bologna, Italy)**
12:30 p.m. - 12:45 p.m.	Chaperone therapy (Migalastat)	**Federico Pieruzzi (Monza, Italy)**
12:45 p.m. - 1:00 p.m.	Pegunigalsidase alfa	**Antonio Pisani (Naples, Italy)**
1:00 p.m. - 1:30 p.m.	**Round Table**: When to use ERT or Oral Therapy. When to use new and "old" drugs. When to Switch.	**Sandro Feriozzi (Roma, Italy), Antonio Pisani Naples, Italy), Federico Pieruzzi (Monza, Italy), Francesco Porta (Turin, Italy)**

KIDNEY AND PREGNANCY		
Chairs	**Gabriella Moroni (Milan, Italy), Gianfranca Cabiddu (Cagliari, Italy)**	
Table of Discussants	**Maria Izabel De Holanda (Rio de Janeiro, Brazil), Savino Sciascia (Turin, Italy)**	
1:30 p.m. - 1:50 p.m.	Pre Eclampsia: from bench to bedside and from bedside to bench	**Vesna Garovic (Rochester, MN, USA)**
1:50 p.m. - 2:10 p.m.	Pre Eclampsia in CKD: *liaisons dangereuses*	**Giorgina Piccoli (Le Mans, France)**
2:10 p.m. - 2:30 p.m.	Taking care of CKD and Pregnancy at Mayo Clinic	**Andrea Kattah (Rochester, MN, USA)**
2:30 p.m. - 2:50 p.m.	Gender Issues in Hypertension: our knowledge is a must	**Francesca Mallamaci (Reggio Calabria, Italy)**
2:50 p.m. - 3:20 p.m.	Plenary Discussion	

KIDNEY TRANSPLANTATION	
Chairs	**Riccardo Cao (Cagliari, Italy), Roberto Littera (Cagliari, Italy)**
Table of Discussants:	**Alberto Rosati (Florence, Italy), Wisit Cheungpasitporn (Rochester, MN, USA), Lucrezia Furian (Padua, Italy)**

3:20 p.m. - 3:40 p.m.	New Approaches to the Treatment of Chronic Antibody Mediated Rejection	**Naim Issa (Rochester, MN, USA)**
3:40 p.m. - 4:00 p.m.	Chronic Antibody Mediated rejection: The influence of minor-HLA locus on the survival of the graft-personal experience and proposal of study	**Antonello Pani (Cagliari, Italy)**
4:00 p.m. – 4:20 p.m.	Real-world of Anti-thymocyte Globulin therapy use in kidney transplantation: experience of a single center	**Giacomo Mascia (Cagliari, Italy)**
4:20 p.m. – 4:40 p.m.	Current Therapies in acute T-cell-mediated rejection	**Vincenzo Cantaluppi (Novara, Italy)**
4:40 p.m. - 5:00 p.m.	Epidemiology of cancer and anti-cancer therapy in renal transplant patients	**Franco Citterio (Rome, Italy)**
5.00 p.m. - 5:20 p.m.	Living kidney donor outcomes	**Naim Issa (Rochester, MN, USA)**
5:20 p.m. - 5:40 p.m.	Incorporation of Genetic Studies in the Kidney Transplant: the role of genetic testing.	**Mireille El Ters (Rochester, MN, USA)**
5:40 p.m. - 6:10 p.m.	Plenary discussion	

SUNDAY, JUNE 1ST

EXPANDING HORIZONS IN GLOMERULAR AND TUBULOINTERSTITIAL NEPHROPATHIES		
Chairs	**Fernando Fervenza (Rochester, MN, USA), Dario Roccatello (Turin, Italy), Antonello Pani (Cagliari, Italy)**	
Table of Discussants	**Giuseppe Gigliotti (Eboli, Italy), Roberto Scarpioni (Piacenza, Italy), Francesca Viazzi (Genoa, Italy)**	
8:00 a.m. - 8:20 a.m.	Tubulointerstitial toxic nephropathies	**Mark Perazella (New Haven, CT, USA)**
8:20 a.m. - 8:40 a.m.	Identification of new and putative antigens in MN: Sardinian experience	**Nicola Lepori (Cagliari, Italy)**
8:40 a.m. - 9:00 a.m.	Precision Medicine for Kidney Disease: Multiomics Integration	**Laura Barisoni (Durham, NC, USA)**
9:00 a.m. - 9:20 a.m.	MGRS: classification and clinical presentation	**Andrea Angioi (Cagliari, Italy)**
9:20 a.m. - 9:40 a.m.	MGRS: Treatment (Hematologist-nephrologist teamwork in ARNAS Brotzu model)	**Daniele Derudas (Cagliari, Italy)**
09:40 a.m. - 10:00 a.m.	How to treat multiple myeloma with renal involvement	**Hayman Suzanne (Rochester, MN, USA)**
10:00 a.m. - 10:40 a.m.	Plenary discussion	

SUNDAY, JUNE 1ST

GENETICS FOR NEPHROLOGISTS (CKD and others)		
Chairs	**Giovambattista Capasso (Napoli, Italy), Doloretta Piras (Cagliari, Italy)**	
Table of discussants	**Francesco Cucca (Sassari, Italy), Giammarco Ghiggeri (Genoa, Italy), Sabrina Giglio (Cagliari, Italy), Francesco Trepiccione (Naples, Italy)**	
10:40 a.m. - 11:00 a.m.	Renal Progenitors Derived from Urine for Personalized Diagnosis of Kidney Diseases	**Elena Lazzeri (Florence, Italy)**
11:00 a.m. - 11:20 a.m.	Aging Kidney, experience in Sardinian Population	**Doloretta Piras (Cagliari, Italy)**
11:20 a.m. - 11:40 a.m.	Clinical features and Genetic testing in an inherited form of NS	**Simone Sanna Cherchi (New York, USA)**
11:40 a.m. - 12:00 p.m.	Clinical exome sequencing in the diagnostic of kidney diseases	**Silvia Deaglio (Turin, Italy)**
12:00 p.m. - 12:20 p.m.	Clinical Significance of the Cystic Phenotype in Alport Syndrome	**Claudia Izzi (Brescia, Italy)**
12:20 p.m. - 1:00 p.m.	Plenary discussion	

LUNCH MEETING: ARTIFICIAL INTELLIGENCE IN NEPHROLOGY		
1:00 p.m. - 1:30 p.m.	Digital Health & Technology in Nephrology and Critical Care Nephrology – focusing on inpatient and ICU settings.	**Kianoush Kashani (Rochester, MN, USA)**
1:30 p.m. - 2:00 p.m.	Generative AI in Kidney Care: Applications and Future Perspectives – focusing on Generative AI and outpatient-based practice.	**Wisit Cheungpasitporn (Rochester, MN, USA)**
2:00 p.m. 2:30 p.m.	How good is AI in making medical risk predictions?	**Pietro Ravani (Calgary, Canada)**

2:30 p.m. - 3:00 p.m.	Standard and new treatments of hyperkalemia	**Biff Palmer (Dallas, TX, USA)**
3:00 p.m. - 3:30 p.m.	New statements on anemia treatment in uremia	**Francesco Locatelli (Lecco, Italy)**

SUNDAY, JUNE 1ST

RENAL REPLACEMENT TREATMENTS AND ABSORPTION IN ACUTE AND CHRONIC PATIENTS		
Chairs	**Antonio Santoro (Bologna, Italy), Paolo Lentini (Bassano del Grappa, Italy)**	
Table of Discussants	**Vincenzo La Milia (Lecco, Italy), Stefania Maxia (Cagliari, Italy), Giorgio Battaglia (Catania, Italy), Hongli Lin (Beijing, China), Vincenzo Cantaluppi (Novara, Italy)**	
3:30 p.m. - 3:50 p.m.	Hemoadsorption-hemodialysis (HAHD) in ESKD patients: insights from international consensus conference	**Claudio Ronco (Vicenza, Italy)**
3:50 p.m. - 4:10 p.m.	Uremic Toxins and Cardiovascular Damage: Pathophysiological Insights and Clinical Implications	**Mario Cozzolino (Milan, Italy)**
4:10 p.m. - 4:30 p.m.	The choice of the membrane in RRT patients	**Marco Pozzato (Turin, Italy)**
4:30 p.m. 4:50 p.m.	Insights in the management of fluid overload and diuretic resistance	**Renato Eick (Porto Alegre, Brasil)**
4:50 p.m. - 5:10 p.m.	Integration for hemoadsorption in acute patients: practical tips	**Matteo Floris (Cagliari, Italy)**
5:10 p.m. - 5:30 p.m.	EBP in luogo di CRRT	**Diego Atzeni (Cagliari, Italy)**
5:30 p.m. – 6:00 p.m.	Plenary Discussion	

HONORARY PRESIDENTS

Paolo Altieri, Richard Glassock, Claudio Ponticelli

SCIENTIFIC SECRETARIAT

Andrea Angioi, Davide Argiolas, Gianfranca Cabiddu, Fernando Fervenza, Matteo Floris, Nicola Lepori, Giacomo Mascia, Antonello Pani, Doloretta Piras, Dario Roccatello

Università degli Studi di Cagliari

Azienda Ospedaliera "ARNAS G. Brotzu" - Cagliari

Università di Torino

Mayo Clinic Rochester (MN) USA

SECRETARY ASSISTANT

Maria Laura Lecca

Azienda Ospedaliera "ARNAS G. Brotzu" - Cagliari

lauralecca@aob.it

ORGANIZING SECRETARIAT

Sardiniameeting Srl
Professional Conference Organizer
Viale La Playa, 7 - 09123 Cagliari
Tel. +39 070664334 - Mob. +39 3294870166
info@sardiniameeting.it www.sardiniameeting.it